NIH Grants $2 million to Symbiotix to Advance Treatment for IBD

NIH Grants $2 million to Symbiotix to Advance Treatment for IBD
The National Institutes of Health’s (NIH) National Institute of Diabetes and Digestive and Kidney Diseases recently granted Symbiotix Biotherapies $2 million to support research and of development of Polysaccharide A (PSA), the first potentially therapeutic molecule to emerge from the human microbiome and a possible new therapeutic avenue for diseases such as inflammatory bowel disease (IBD). The Phase II Small Business Technology Transfer award will enable completion of fundamental translational research activities and also support the development/manufacturing process to move PSA into human trials as a new treatment for immune-mediated conditions such as IBD. PSA is a first-in-class oral therapy that activates regulatory T cells, which exert an anti-inflammatory effect through the production of IL-10, an anti-inflammatory cytokine that plays an essential immunoregulator role in the intestinal tract. This is the fourth award that Symbiotix has received from NIH for its development programs, now totalling more than $5 million in NIH support. “Many of the existing FDA-approved drugs for IBD are ineffective in large subsets of patients or have significant side effects,” Sarkis Mazmanian, PhD, the Louis & Nelly Soux Professor of Microbiology in the Division of Biology & Biological Engineering at the California Institute of Technology, said in a press release. “This award will provide funding to advance PSA as a possible safe and effective new oral therapy for man
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *